Guidelines from diabetes and heart disease societies name these meds specifically as first choices to treat people with T2D who have established cardiovascular disease (CVD). SGLT2’s also prevent hospitalization for heart failure. Although the details of research studies are always nuanced, and different drugs have different levels of study outcomes, in general the evidence is very strong that these medicines significantly decrease risk of death from all causes, heart attacks, sudden death, and stroke.They don’t cause low blood sugar by themselves.Here are some of the good things they do: And there’s more to come! That’s what happens when you have a good thing going. Whew – that’s a lot of names and choices. The second are SGLT2i’s (ignore that too, for now) named Invokana, Jardiance, Farxiga, and Steglatro. The first are called GLP1-RA’s (to be explained, below) which include brand names Byetta, Victoza, Bydureon-BCise, Trulicity, and Ozempic. Game ChangersĪll that changed with the release of two newer classes of diabetes medicines. TREATING SEVERE HYPOGLYCEMIA: Enduring CME for HCPs – 1.0 CEUsĪmong the dirty little secrets of the older diabetes medicines was that they usually made you gain weight, they could cause low blood sugar suddenly and unexpectedly, and they had no particular benefit to the most important consequence of type 2 diabetes (T2D) – heart disease.MAKING THE CONNECTION: Enduring CME for HCPs – 4.0 CEUs.
#HEARTS MEDICINE SEASON ONE EPISODE 3 HELP UPDATE#
UPDATE ON INHALED & RAPID ACTING INSULIN: Online CME for HCPs – 1.0 CEUs – JULY 21, 2022.
0 kommentar(er)
